Arena Pharmaceuticals Inc. (ARNA)

40.03
0.35 0.87
NASDAQ : Health Technology
Prev Close 40.38
Open 40.40
Day Low/High 39.30 / 40.74
52 Wk Low/High 11.30 / 45.85
Volume 629.00K
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 47.78M
Market Cap 1.91B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ARNA May 11th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 11th contracts and identified one put and one call contract of particular interest.

My Biggest Concern About This Stock Market

My Biggest Concern About This Stock Market

There's a worrisome scenario that could develop this afternoon.

Here's When You Can Buy Twitter's Stock

Here's When You Can Buy Twitter's Stock

There just aren't any pockets of strong momentum right now.

Arena Pharmaceuticals Reports Positive Phase 2 Results From The OASIS Trial For Etrasimod In Patients With Ulcerative Colitis

Arena Pharmaceuticals Reports Positive Phase 2 Results From The OASIS Trial For Etrasimod In Patients With Ulcerative Colitis

- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks

Arena Pharmaceuticals To Host Key Opinion Leader Event On S1P Modulation And Etrasimod In Autoimmune Diseases On January 29 In New York City

Arena Pharmaceuticals To Host Key Opinion Leader Event On S1P Modulation And Etrasimod In Autoimmune Diseases On January 29 In New York City

- Jerold Chun, M.D., Ph.D. (Sanford Burnham Prebys), and Eric Gershwin, M.D. (UC Davis Health), to Present

Arena Pharmaceuticals Reaches Analyst Target Price

Arena Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Arena Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.

Arena Pharmaceuticals And Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

Arena Pharmaceuticals And Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

The company just beat a bench mark, previously set by Johnson & Johnson.

Xilinx, Arena Pharmaceuticals, Magellan Midstream: 'Mad Money' Lightning Round

Xilinx, Arena Pharmaceuticals, Magellan Midstream: 'Mad Money' Lightning Round

Jim Cramer is bullish on Xilinx, Arena Pharmaceuticals, Magellan Midstream, Altria and Bank of Montreal.

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)

Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.

This $3 Biotech Stock Is Making an 11% Move Thursday

This $3 Biotech Stock Is Making an 11% Move Thursday

In focus.

TheStreet Quant Rating: D (Sell)